All News

Advocacy fosters professional development, creates better working conditions, and enhances patient care.

The new guidelines urge health care professionals to offer local anesthetics and other medications for intrauterine device (IUD) insertions and other gynecologic procedures.

The regimen, which consists of durvalumab and Bacillus Calmette-Guerin, offers new hope to patients with high-risk non-muscle-invasive bladder cancer.

Omalizumab expands its role in allergy management, now FDA-approved for food allergies, showcasing potential for broader applications in allergic rhinitis.

A new study reveals that heart failure patients with implantable devices are more likely to receive the pneumococcal conjugate vaccine 13, impacting vaccination rates and mortality.

Specialty pharmacists enhance CKD management through personalized care, medication adherence strategies, and collaboration with health care providers.

These pharmacists help bridge gaps for patients in difficult situations.

The FDA approves retifanlimab for advanced anal cancer, offering new hope with improved survival rates and treatment options for patients.

Ibrutinib offers comparable survival outcomes for high-risk chronic lymphocytic leukemia patients, challenging traditional prognostic markers in real-world settings.

Pharmacy staff can be instrumental members of shortage management teams.

In patients with synchronous metastatic colorectal cancer treated without curative intent, high low-density lipoprotein (LDL) cholesterol was associated with poor survival.

Cure Rare Disease's CRD-002 receives FDA orphan drug designation, advancing hope for SCA3 treatment with innovative oligonucleotide therapy.

With Oregon, Colorado, and New Mexico legalizing psilocybin-assisted therapy, opportunities for treatment are expanding.

The approved injection contains dihydroergotamine (DHE), which is the same medication used in hospitals, in a ready-to-use device.

Explore the latest advancements in RSV vaccination strategies for newborns, focusing on maternal immunization and post-birth protection options.

Logan Schneider, MD, highlights the importance of integrating patient-reported outcomes into clinical trials to better capture the full therapeutic impact of low-sodium oxybate (Xywav) beyond traditional sleep metrics.

The announcement came shortly before updated results from the SURMOUNT-5 clinical trial, which found Zepbound had superior weight-loss effects over Wegovy.

The seasonal surge in skin irritations underscores the ongoing need for effective and convenient remedies.

Tirzepatide outperforms semaglutide in weight loss, achieving an average reduction of 20.2% in a pivotal trial for obesity management.

The data are from the phase 2 iMMagine-1 study.

Emrelis is a groundbreaking treatment for advanced non-small cell lung cancer, targeting high c-Met protein overexpression.

The FDA approved belzutifan, the first oral treatment for pheochromocytoma and paraganglioma, offering a new treatment pathway for patients with these rare tumors.

New trial results reveal icotrokinra's effectiveness in achieving significant skin clearance for challenging scalp and genital psoriasis.

Effectively communicating research findings to patients, health care professionals, and policy payers is necessary for engagement.

Like other high-risk groups, children with sickle cell disease have a heightened risk of invasive pneumococcal disease, even if they receive proper pneumococcal conjugate vaccine coverage.